UCB's Global Corporate Website
Welcome to UCB in the United States

Apr

11

Our Leadership and Legacy in Epilepsy and Rare Syndromes

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Jun

02

Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Jun

13

UCB Builds Partnerships with Rare Epilepsy Syndrome Patient Groups